mega fishing game In the fast-paced world of online search and information retrieval, Reddit, the popular community-driven website, has stepped up its game with the launch of a revolutionary AI-powered search tool called "Answers". This move has set the stage for a potential showdown with tech giant Google in the domain of information search.PONTE VEDRA, Fla., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that Guy Guglielmino joined the Company as Chief Commercial Officer. In this new position, Mr. Guglielmino will lead Treace’s commercial efforts and play a pivotal role in driving the Company’s next phase of rapid innovation, strategic product commercialization, and growth. “I am thrilled to welcome Guy to the Treace team,” said John T. Treace, CEO, Founder and Board Member of Treace. “With a wealth of diverse medical technology industry experience, a demonstrated track record of strong customer engagement, leadership in innovation and product development, and a proven ability to deliver exceptional market growth, Guy is ideally suited to lead our commercial efforts.” “I’ve always admired and respected Treace, having watched the team create and lead in entirely new market segments,” said Mr. Guglielmino. “Treace has established a new standard with an approach that deeply understands their customers’ unmet needs, resulting in groundbreaking innovations that democratize the practice of the surgical treatment of bunions and midfoot deformities. I look forward to working with John and the Treace leadership team to deliver class-leading innovation, product commercialization, and sustained market performance.” Mr. Guglielmino joins Treace with deep medical technology industry expertise, having served in diverse senior leadership roles. Most recently, Mr. Guglielmino was President, Recovery Sciences at Enovis. Prior to that, he held senior Marketing roles at Enovis, Wright Medical, and at Bausch + Lomb. Mr. Guglielmino received his Bachelor of Science in Business & Entrepreneurship and his MBA from the Rochester Institute of Technology. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements, including, but not limited to, the Company’s expectations of innovation, product commercialization, market performance, and growth. Forward-looking statements are based on management’s current assumptions and expectations of future events and trends, which affect or may affect the Company’s business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Factors that could cause actual results or other events to differ materially from those contemplated in this press release can be found in the Risk Factors section of Treace’s public filings with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2023, which was filed with the SEC on February 27, 2024, and its subsequent SEC filings. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of their date and, except to the extent required by law, the Company undertakes no obligation to update these statements, whether as a result of any new information, future developments or otherwise. Internet Posting of Information Treace routinely posts information that may be important to investors in the “Investor Relations” section of its website at www.treace.com . The Company encourages investors and potential investors to consult the Treace website regularly for important information about Treace. About Treace Medical Concepts Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 67 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty® 3D Bunion Correction® System – a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. To further support the needs of bunion patients, Treace has introduced its Adductoplasty® Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities. The Company continues to expand its footprint in the foot and ankle market with the introduction of its SpeedPlateTM Rapid Compression Implants, an innovative fixation platform with broad versatility across Lapiplasty® and Adductoplasty® procedures, as well as other common bone fusion procedures of the foot. For more information, please visit www.treace.com . To learn more about Treace, connect with us on LinkedIn , X , Facebook and Instagram . Contacts: Treace Medical Concepts Mark L. Hair Chief Financial Officer mhair@treace.net (904) 373-5940 Investors: Gilmartin Group Vivian Cervantes IR@treace.netOPAL Fuels Appoints Darrell Birck as Executive Vice President of BiogasPhiladelphia Eagles star Saquon Barkley became the ninth player in NFL history to rush for 2,000 yards in a season on Sunday. Barkley entered the game against the visiting Dallas Cowboys needing 162 yards to join the exclusive club. He reached the milestone with a 23-yard run with about 11 minutes remaining in the fourth quarter and Philadelphia leading 34-7. That gave him 167 for the day on 31 carries and 2,005 for the season. With one game remaining, Barkley has a chance to break Eric Dickerson's NFL single-season record of 2,105 yards, set during a 16-game season in 1984. In addition to Dickerson, the others to rush for 2,000 yards are Adrian Peterson, Jamal Lewis, Barry Sanders, Derrick Henry, Terrell Davis, Chris Johnson and O.J. Simpson. With the Eagles locked into the No. 2 seed in the NFC, it's unclear whether Barkley will play in next weekend's regular-season finale against his former team, the New York Giants. Barkley also broke LeSean McCoy's 2013 franchise record of 2,146 all-purpose yards. --Field Level Media

The players at Plymouth Argyle have already expressed their excitement about learning from Okeoghene and Rooney, citing their enthusiasm and dedication as inspirational. The club's supporters have also welcomed the new coaching addition with open arms, eager to witness the positive impact that Okeoghene and Rooney will have on the team.

Unlike scores of people who scrambled for the blockbuster drugs Ozempic and Wegovy to lose weight in recent years, Danielle Griffin had no trouble getting them. The 38-year-old information technology worker from New Mexico had a prescription. Her pharmacy had the drugs in stock. And her health insurance covered all but $25 to $50 of the monthly cost. For Griffin, the hardest part of using the new drugs wasn’t access. It was finding out that the much-hyped medications didn’t really work for her. “I have been on Wegovy for a year and a half and have only lost 13 pounds,” said Griffin, who watches her diet, drinks plenty of water and exercises regularly. “I’ve done everything right with no success. It’s discouraging.” In clinical trials, most participants taking Wegovy or Mounjaro to treat obesity lost an average of 15% to 22% of their body weight — up to 50 pounds or more in many cases. But roughly 10% to 15% of patients in those trials were “nonresponders” who lost less than 5% of their body weight. Now that millions of people have used the drugs, several obesity experts told The Associated Press that perhaps 20% of patients — as many as 1 in 5 — may not respond well to the medications. It's a little-known consequence of the obesity drug boom, according to doctors who caution eager patients not to expect one-size-fits-all results. “It's all about explaining that different people have different responses,” said Dr. Fatima Cody Stanford, an obesity expert at Massachusetts General Hospital The drugs are known as GLP-1 receptor agonists because they mimic a hormone in the body known as glucagon-like peptide 1. Genetics, hormones and variability in how the brain regulates energy can all influence weight — and a person's response to the drugs, Stanford said. Medical conditions such as sleep apnea can prevent weight loss, as can certain common medications, such as antidepressants, steroids and contraceptives. “This is a disease that stems from the brain,” said Stanford. “The dysfunction may not be the same” from patient to patient. Despite such cautions, patients are often upset when they start getting the weekly injections but the numbers on the scale barely budge. “It can be devastating,” said Dr. Katherine Saunders, an obesity expert at Weill Cornell Medicine and co-founder of the obesity treatment company FlyteHealth. “With such high expectations, there’s so much room for disappointment.” That was the case for Griffin, who has battled obesity since childhood and hoped to shed 70 pounds using Wegovy. The drug helped reduce her appetite and lowered her risk of diabetes, but she saw little change in weight. “It’s an emotional roller coaster,” she said. “You want it to work like it does for everybody else.” The medications are typically prescribed along with eating behavior and lifestyle changes. It’s usually clear within weeks whether someone will respond to the drugs, said Dr. Jody Dushay, an endocrine specialist at Beth Israel Deaconess Medical Center. Weight loss typically begins right away and continues as the dosage increases. For some patients, that just doesn't happen. For others, side effects such as nausea, vomiting and diarrhea force them to halt the medications, Dushay said. In such situations, patients who were counting on the new drugs to pare pounds may think they’re out of options. “I tell them: It's not game over,” Dushay said. Trying a different version of the new class of drugs may help. Griffin, who didn't respond well to Wegovy, has started using Zepbound, which targets an additional hormone pathway in the body. After three months of using the drug, she has lost 7 pounds. “I'm hoping it's slow and steady,” she said. Other people respond well to older drugs, the experts said. Changing diet, exercise, sleep and stress habits can also have profound effects. Figuring out what works typically requires a doctor trained to treat obesity, Saunders noted. “Obesity is such a complex disease that really needs to be treated very comprehensively,” she said. “If what we’re prescribing doesn’t work, we always have a backup plan.” The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.

The United States' recent diplomatic successes in the Middle East have been nothing short of remarkable. With the signing of the Abraham Accords between Israel, the United Arab Emirates, Bahrain, Sudan, and Morocco, the US has managed to broker peace deals that were previously unthinkable. These agreements have not only helped to stabilize the region but have also bolstered America's standing as a key player in the Middle East's geopolitical landscape.Title: Insights into November Economic Highlights from Value-Added Tax Invoice Data: Policy Combinations Yielding Results, Economic Stability Strengthening Continues

Franklin BSP Realty Trust, Inc. ( NYSE:FBRT – Get Free Report ) announced a quarterly dividend on Monday, December 16th, NASDAQ Dividends reports. Stockholders of record on Tuesday, December 31st will be paid a dividend of 0.355 per share on Friday, January 10th. This represents a $1.42 annualized dividend and a dividend yield of 11.20%. The ex-dividend date is Tuesday, December 31st. Franklin BSP Realty Trust has a dividend payout ratio of 92.8% indicating that its dividend is currently covered by earnings, but may not be in the future if the company’s earnings decline. Equities analysts expect Franklin BSP Realty Trust to earn $1.52 per share next year, which means the company should continue to be able to cover its $1.42 annual dividend with an expected future payout ratio of 93.4%. Franklin BSP Realty Trust Trading Down 0.5 % Shares of Franklin BSP Realty Trust stock opened at $12.68 on Friday. Franklin BSP Realty Trust has a 12-month low of $11.99 and a 12-month high of $14.11. The stock has a market capitalization of $1.04 billion, a P/E ratio of 15.46 and a beta of 1.40. The company has a 50-day simple moving average of $12.97 and a 200 day simple moving average of $13.01. The company has a quick ratio of 90.45, a current ratio of 90.45 and a debt-to-equity ratio of 3.67. Analyst Ratings Changes Read Our Latest Stock Analysis on FBRT Franklin BSP Realty Trust Company Profile ( Get Free Report ) Benefit Street Partners operates as a self-managed real estate investment trust (REIT). BSP earns income from investing in a leveraged portfolio of residential mortgage pass-through securities consisting almost exclusively of adjustable-rate mortgage (ARM) securities issued and guaranteed by government-sponsored enterprises, either Federal National Mortgage Association (Fannie Mae) or Federal Home Loan Mortgage Corporation (Freddie Mac) (together, the government-sponsored enterprises (GSEs)), or by an agency of the federal government, Government National Mortgage Association (Ginnie Mae). Recommended Stories Receive News & Ratings for Franklin BSP Realty Trust Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Franklin BSP Realty Trust and related companies with MarketBeat.com's FREE daily email newsletter .

The UN's marathon climate summit neared the finish line early Sunday, with nations due to approve or reject a hotly-disputed deal for wealthy historic emitters to provide at least $300 billion to poorer countries that had demanded much more. After an exhausting two weeks of negotiations in Azerbaijan's Caspian Sea capital of Baku, COP29 president Mukhtar Babayev declared open the final summit plenary after midnight, two days after the conference was officially scheduled to end. A final text was released following several sleepless nights for negotiators, with tensions boiling over as small islands states and the world's poorest countries walked out of one meeting. "This package is an affront to us. We are the countries that have the most at stake," said Tina Stege, climate envoy of the Marshall Islands, an atoll nation threatened by rising seas. Top German negotiator Jennifer Morgan told AFP that countries would be presented a "take it or leave it" deal. Before the closing session, delegates huddled in small groups on the floor of the main conference room inside Baku's sports stadium to pore over copies of the latest draft deal line by line. "I know that none of us want to leave Baku without a good outcome," Babayev said. A number of countries have accused Azerbaijan, an authoritarian oil and gas exporter, of lacking the experience and will to meet the moment, as the planet again sets temperature records and faces rising deadly disasters. Small island nations and impoverished African states on Saturday angrily stormed out of a meeting with Azerbaijan, saying their concerns had been ignored. "I think it caught a lot of people by surprise," said Brazil's climate envoy, Ana Toni. "It all happened very quickly." The walkout triggered an emergency meeting between those nations and top negotiators from the European Union, United States and Britain with the COP29 presidency in which new proposals were made. Wealthy countries and small island nations have also been concerned by efforts led by Saudi Arabia to water down calls from last year's summit to phase out fossil fuels. The final text proposes that rich nations raise to at least $300 billion a year by 2035 their commitment to poorer countries to fight climate change. It is up from $100 billion now provided by wealthy nations under a commitment set to expire -- and from $250 billion proposed in a draft Friday. That offer was slammed as offensively low by developing countries, which have demanded at least $500 billion to build resilience against climate change and cut emissions. Sierra Leone's climate minister Jiwoh Abdulai, whose country is among the world's poorest, called the draft "effectively a suicide pact for the rest of the world". Developing power Brazil pleaded for at least some progress and said it would seek to build on it when it leads COP30 next year in the Amazon gateway of Belem. "After the difficult experience that we're having here in Baku, we need to reach some outcome that is minimally acceptable in line with the emergency we're facing," Brazil's environment minister Marina Silva told delegates. As staff at the cavernous and windowless stadium began packing up, diplomats rushed between meetings, some armed with food and water in anticipation of another late night. Panama's outspoken negotiator, Juan Carlos Monterrey Gomez, warned not to repeat the failure of COP15 in Copenhagen in 2009. "I'm sad, I'm tired, I'm disheartened, I'm hungry, I'm sleep-deprived, but there is a tiny ray of optimism within me because this cannot become a new Copenhagen," he told reporters. Climate activists shouted "shame" as US climate envoy John Podesta walked the halls. "Hopefully this is the storm before the calm," he said. Wealthy nations say it is politically unrealistic to expect more in direct government funding. Donald Trump, a sceptic of both climate change and foreign assistance, returns to the White House in January and a number of other Western countries have seen right-wing backlashes against the green agenda. The draft deal posits a larger overall target of $1.3 trillion per year to cope with rising temperatures and disasters, but most would come from private sources. South African Environment Minister Dion George, however, said: "I think being ambitious at this point is not going to be very useful." The United States and EU have wanted newly wealthy emerging economies like China -- the world's largest emitter -- to chip in. The final draft encouraged developing countries to make contributions on a voluntary basis, reflecting no change for China which already pays climate finance on its own terms. The EU and other countries have also tussled with Saudi Arabia over including strong language on moving away from fossil fuels, which negotiators say the oil-producing country has resisted. "We will not allow the most vulnerable, especially the small island states, to be ripped off by the new, few rich fossil fuel emitters," said German Foreign Minister Annalena Baerbock. bur-np-sct-lth/jmBy openly stating its willingness to answer questions from regulators, Nvidia is sending a clear message that it is committed to working collaboratively with regulatory authorities to address any issues that may arise. This proactive approach not only reflects Nvidia's commitment to regulatory compliance but also demonstrates its respect for the rule of law and its willingness to uphold the highest standards of corporate governance.